247 related articles for article (PubMed ID: 28649878)
1. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
Takeuchi T; Ishida K; Shiraki K; Yoshiyasu T
Mod Rheumatol; 2018 Jan; 28(1):48-57. PubMed ID: 28649878
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus.
Ishida K; Shiraki K; Yoshiyasu T
Drugs R D; 2015 Dec; 15(4):307-17. PubMed ID: 26386566
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis.
Takeuchi T; Kawai S; Yamamoto K; Harigai M; Ishida K; Miyasaka N
Mod Rheumatol; 2014 Jan; 24(1):8-16. PubMed ID: 24261753
[TBL] [Abstract][Full Text] [Related]
4. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study.
Suzuki M; Takahashi N; Kida D; Hirano Y; Kato T; Yabe Y; Oguchi T; Fujibayashi T; Hayashi M; Asai S; Ishiguro N; Kojima T
Int J Rheum Dis; 2019 Dec; 22(12):2199-2205. PubMed ID: 31647174
[TBL] [Abstract][Full Text] [Related]
6. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
[TBL] [Abstract][Full Text] [Related]
8. Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.
Takakubo Y; Tamaki Y; Hirayama T; Iwazaki K; Yang S; Sasaki A; Nakano H; Konttinen YT; Takagi M
Rheumatol Int; 2012 Nov; 32(11):3487-94. PubMed ID: 22065071
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.
Koike T; Harigai M; Inokuma S; Inoue K; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Freundlich B; Suzukawa M
J Rheumatol; 2009 May; 36(5):898-906. PubMed ID: 19332630
[TBL] [Abstract][Full Text] [Related]
11. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.
Harigai M; Ishiguro N; Inokuma S; Mimori T; Ryu J; Takei S; Takeuchi T; Tanaka Y; Takasaki Y; Yamanaka H; Watanabe M; Tamada H; Koike T
Mod Rheumatol; 2016 Jul; 26(4):491-8. PubMed ID: 26635183
[TBL] [Abstract][Full Text] [Related]
12. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
Ogasawara M; Tamura N; Kageyama M; Onuma S; Kusaoi M; Toyama S; Sekiya F; Matsudaira R; Nawata M; Tada K; Matsushita M; Kempe K; Amano H; Morimoto S; Yamaji K; Takasaki Y
Clin Rheumatol; 2012 Feb; 31(2):251-7. PubMed ID: 21773713
[TBL] [Abstract][Full Text] [Related]
13. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis.
Yokota K; Akiyama Y; Asanuma Y; Miyoshi F; Sato K; Mimura T
Rheumatol Int; 2009 Feb; 29(4):459-61. PubMed ID: 18802706
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H
Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate.
Kitahama M; Nakajima A; Inoue E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2013 Jul; 23(4):788-93. PubMed ID: 22975732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
